{
    "id": 16230,
    "fullName": "LYN D189Y",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "LYN D189Y lies within the SH2 domain of the Lyn protein (UniProt.com). D189Y results in increased Lyn kinase activity and increased phosphorylation of downstream targets including FAK, IGF-1R, EGFR, HER3, STAT3, MAPK and AKT, and enhanced growth of cells in culture (PMID: 25401474).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4067,
        "geneSymbol": "LYN",
        "terms": [
            "LYN",
            "JTK8",
            "p53Lyn",
            "p56Lyn"
        ]
    },
    "variant": "D189Y",
    "createDate": "01/05/2016",
    "updateDate": "01/20/2016",
    "referenceTranscriptCoordinates": {
        "id": 159614,
        "transcript": "NM_002350",
        "gDna": "chr8:g.55952043G>T",
        "cDna": "c.565G>T",
        "protein": "p.D189Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3854,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) resensitized ESR1-positive breast cancer cells harboring PIK3CA mutations and expressing LYN D189Y to Falsodex (fulvestrant) in culture (PMID: 25401474).",
            "molecularProfile": {
                "id": 16502,
                "profileName": "ESR1 pos LYN D189Y PIK3CA mut"
            },
            "therapy": {
                "id": 3372,
                "therapyName": "Dasatinib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3821,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of LYN D189Y conferred resistance to Falsodex (fulvestrant)-mediated growth inhibition in ESR1-positive breast cancer cells harboring PIK3CA mutations in culture (PMID: 25401474).",
            "molecularProfile": {
                "id": 16502,
                "profileName": "ESR1 pos LYN D189Y PIK3CA mut"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16501,
            "profileName": "LYN D189Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16502,
            "profileName": "ESR1 pos LYN D189Y PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 159614,
            "transcript": "NM_002350",
            "gDna": "chr8:g.55952043G>T",
            "cDna": "c.565G>T",
            "protein": "p.D189Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}